{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-332736","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2026-08-04T20:02:18+00:00","discovered_at":"2026-08-04T20:04:00.992586+00:00","generated_at":"2026-08-04T20:05:02.414041+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Syndax Q2 2026 revenue $72.8M; Revuforj net revenue $54.7M (+91% YoY); Niktimvo $60.3M (+67%)","bullets":["Total revenue $72.8M (Revuforj $54.7M, Niktimvo collaboration $18.1M); H1 2026 net loss $49.4M vs $71.8M prior year.","Cash $575.1M; expects profitability; full-year 2026 R&D+SG&A ~$400M excl. $50M stock comp.","Pipeline expanded: SNDX-4321 (allosteric EGFR inhibitor for NSCLC) IND by end 2026; SNDX-62122 (menin inhibitor for MF) IND in 2027.","Topline data expected in 4Q26 from Phase 2 trials of axatilimab in IPF and frontline cGVHD.","Revuforj prescriptions ~1,500 in Q2 (+121% YoY); average treatment duration increasing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-332736","json":"https://secwatch.observer/filing/0001193125-26-332736.json","markdown":"https://secwatch.observer/filing/0001193125-26-332736.md","text":"https://secwatch.observer/filing/0001193125-26-332736.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526332736/0001193125-26-332736-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526332736/sndx-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T20:05:02.414041+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}